Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions

Biomaterials

Volumn 35, Issue 27, 2014, Pages 8002-8014

  Liu, Lisha ^a   He, Hongliang ^a   Zhang, Mengyuan ^a   Zhang, Shuangshuang ^a   Zhang, Wenli ^a   Liu, Jianping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Atheroprotective efficacy; Atherosclerotic lesions targeting; CD44; HA; RHDL; SR BI

Indexed keywords

ENZYME INHIBITION; LIPOPROTEINS; ORGANIC ACIDS;

ATHEROPROTECTIVE EFFICACY; ATHEROSCLEROTIC LESIONS; CD44; HA; RHDL; SR-BI;

HYALURONIC ACID;

GELATINASE B; HERMES ANTIGEN; HIGH DENSITY LIPOPROTEIN; HYALURONIC ACID; MEVINOLIN; SCAVENGER RECEPTOR BI; DRUG CARRIER; NANOMATERIAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTERIAL WALL THICKNESS; ARTICLE; BINDING AFFINITY; CELL INFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG RELEASE; DRUG UPTAKE; EX VIVO STUDY; EXPERIMENTAL ATHEROSCLEROSIS; IN VITRO STUDY; MACROPHAGE FUNCTION; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT MODEL; SINGLE DRUG DOSE; SURFACE CHARGE; TISSUE DISTRIBUTION; UPREGULATION; ANIMAL; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; MACROPHAGE; METABOLISM; PATHOLOGY; RABBIT; STATIC ELECTRICITY; THORACIC AORTA; ULTRASTRUCTURE;

ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FLUORESCENT ANTIBODY TECHNIQUE; HYALURONIC ACID; LIPOPROTEINS, HDL; LOVASTATIN; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; NANOSTRUCTURES; PARTICLE SIZE; RABBITS; STATIC ELECTRICITY; TISSUE DISTRIBUTION;

EID: 84903439607     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.081     Document Type: Article

References (45)

1. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143.
2. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473(7347):317-325.
3. Charo I.F., Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011, 10(5):365-376.
4. Bruckman M., Jiang K., Simpson E.J., Randolph L., Luyt L.G., Yu X., et al. Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques invivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett 2014, 10.1021/nl404816m.
5. You D.G., Saravanakumar G., Son S., Han H.S., Heo R., Kim K., et al. Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging. Carbohydr Polym 2014, 101:1225-1233.
6. Maiseyeu A., Mihai G., Kampfrath T., Simonetti O.P., Sen C.K., Roy S., et al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. JLipid Res 2009, 50(11):2157-2163.
7. Hamzah J., Kotamraju V.R., Seo J.W., Agemy L., Fogal V., Mahakian L.M., et al. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2011, 108(17):7154-7159.
8. Natarajan P., Ray K.K., Cannon C.P. High-density lipoprotein and coronary heart disease: current and future therapies. JAm Coll Cardiol 2010, 55(13):1283-1299.
9. Damiano M.G., Mutharasan R.K., Tripathy S., McMahon K.M., Thaxton C.S. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 2013, 65(5):649-662.
10. Zhang W., He H., Liu J., Wang J., Zhang S., Zhang S., et al. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials 2013, 34(1):306-319.
11. Zhang W., Gu X., Bai H., Yang R., Dong C., Liu J. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm 2010, 391(1):313-321.
12. Zhang W., Xiao Y., Liu J., Wu Z.-M., Gu X., Xu Y.-M., et al. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int J Pharm 2011, 419(1):314-321.
13. Ji A., Wroblewski J.M., Cai L., de Beer M.C., Webb N.R., van der Westhuyzen D.R. Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. JLipid Res 2012, 53(3):446-455.
14. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33(36):9246-9258.
15. Slevin M., Krupinski J., Gaffney J., Matou S., West D., Delisser H., et al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 2007, 26(1):58-68.
16. Park J., Cho H., Yoon H., Yoon I., Ko S., Shim J., et al. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. JControl Release 2014, 174:98-108.
17. Yang X., Li Y., Li M., Zhang L., Feng L., Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 2013, 334(2):338-345.
18. Bajaj G., Kim M.R., Mohammed S.I., Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. JControl Release 2012, 158(3):386-392.
19. Dufaÿ Wojcicki A., Hillaireau H., Nascimento T.L., Arpicco S., Taverna M., Ribes S., et al. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and invitro targeting of the CD44 receptor. JControl Release 2012, 162(3):545-552.
20. Li J., He Y., Sun W., Luo Y., Cai H., Pan Y., et al. Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging. Biomaterials 2014, 35(11):3666-3677.
21. Yu M., Jambhrunkar S., Thorn P., Chen J., Gu W., Yu C. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale 2013, 5(1):178-183.
22. El-Dakdouki M.H., El-Boubbou K., Kamat M., Huang R., Abela G.S., Kiupel M., et al. CD44 targeting magnetic glyconanoparticles for atherosclerotic plaque imaging. Pharm Res 2013, 1-12. 10.1007/s11095-013-1021-8.
23. Kamat M., El-Boubbou K., Zhu D.C., Lansdell T., Lu X., Li W., et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem 2010, 21(11):2128-2135.
24. Bot P.T., Pasterkamp G., Goumans M.J., Strijder C., Moll F.L., De Vries J.P., et al. Hyaluronic acid metabolism is increased in unstable plaques. Eur J Clin Invest 2010, 40(9):818-827.
25. Gu X., Zhang W., Liu J., Shaw J.P., Shen Y., Xu Y., et al. Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech 2011, 12(4):1200-1208.
26. He H., Liu L., Bai H., Wang J., Zhang Y., Zhang W., et al. Arachidonic acid-modified lovastatin discoidal reconstituted high density lipoprotein markedly decreases the drug leakage during the remodeling behaviors induced by lecithin cholesterol acyltransferase. Pharm Res 2014, 1-21. 10.1007/s11095-013-1273-3.
27. Almalik A., Karimi S., Ouasti S., Donno R., Wandrey C., Day P.J., et al. Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles. Biomaterials 2013, 34(21):5369-5380.
28. Lorenz M., Fechner M., Kalkowski J., Fröhlich K., Trautmann A., Böhm V., et al. Effects of lycopene on the initial state of atherosclerosis in New Zealand White (NZW) rabbits. PLoS One 2012, 7(1):e30808.
29. Chen W., Tang F., Xie B., Chen S., Huang H., Liu P. Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress. Eur J Pharmacol 2012, 674(2):359-364.
30. Haas T.L., Doyle J.L., Distasi M.R., Norton L.E., Sheridan K.M., Unthank J.L. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol 2007, 293(4):H2429-H2437.
31. Shen Y.H., Zhang L., Ren P., Nguyen M.T., Zou S., Wu D., et al. AKT2 confers protection against aortic aneurysms and dissections. Circ Res 2013, 112(4):618-632.
32. Khanna V., Jain M., Singh V., Kanshana J.S., Prakash P., Barthwal M.K., et al. Cholesterol diet withdrawal leads to an initial plaque instability and subsequent regression of accelerated Iliac artery atherosclerosis in rabbits. PLoS One 2013, 8(10):e77037.
33. Li H., Xu H., Sun B. Lipopolysaccharide regulates MMP-9 expression through TLR4/NF-κB signaling in human arterial smooth muscle cells. Mol Med Rep 2012, 6(4):774-778.
34. Diomede L., Albani D., Sottocorno M., Donati M.B., Bianchi M., Fruscella P., et al. Invivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001, 21(8):1327-1332.
35. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203(2):325-330.
36. Akdim F., van Leuven S.I., Kastelein P., John J., Stroes G., Erik S. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?. Curr Pharm Des 2007, 13(10):1003-1012.
37. Ossipov D.A. Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv 2010, 7(6):681-703.
38. Arpicco S., Lerda C., Dalla Pozza E., Costanzo C., Tsapis N., Stella B., et al. Hyaluronic acid-coated liposomes for active targeting of gemcitabine. Eur J Pharm Biopharm 2013, 85(3):373-380.
39. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006, 112(3):630-648.
40. Shah P.K. Inflammation and plaque vulnerability. Cardiovasc Ther 2009, 23(1):31-40.
41. Chen C.-C., Tsai T.-H., Huang Z.-R., Fang J.-Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010, 74(3):474-482.
42. Duivenvoorden R., Tang J., Cormode D.P., Mieszawska A.J., Izquierdo-Garcia D., Ozcan C., et al. Astatin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014, 5:3065. 10.1038/ncomms4065.
43. Croons V., De Meyer I., Houten S.M., Martinet W., Bult H., Herman A.G., et al. Effect of statins on the viability of macrophages and smooth muscle cells. JCardiovasc Pharmacol 2010, 55(3):269-275.
44. Leigh D., Eken J., Beal J., Ganti A., Sahmoun A. Statins use and risk for brain metastasis from lung cancer. Cancer Invest 2011, 29(1):68-72.
45. Pitman W.A., Osgood D.P., Smith D., Schaefer E.J., Ordovas J.M. The effects of diet and lovastatin on regression of fatty streak lesions and on hepatic and intestinal mRNA levels for the LDL receptor and HMG CoA reductase in F1B hamsters. Atherosclerosis 1998, 138(1):43-52.